AICAR vs MOTS-c
How AICAR and MOTS-c compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
AICAR and MOTS-c come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
AICAR vs MOTS-c, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | AICAR | MOTS-c |
|---|---|---|
| What it is | Nucleoside AMPK activator (acadesine) — not a peptide | Mitochondrial-derived peptide (a 16-amino-acid peptide encoded inside mitochondrial DNA) |
| Class / category | Longevity / mitochondrial | Longevity / mitochondrial |
| Evidence tier | Animal-only · Helped · none in humans | Animal-only · Unclear · none in humans |
| Studied / approved for | Perioperative myocardial protection during coronary artery bypass graft surgery; Metabolic disease research | Insulin sensitivity and metabolic health; Exercise capacity / physical performance; Healthy aging / longevity |
| US regulatory status (2026) | research use only (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 5 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | AICAR has been administered intravenously to people in monitored clinical research, but that does not establish the safety of self-directed use for endurance, fat loss, or longevity. There is no approved label, no validated performance dose, and no long-term safety record for that use. Research-market products add separate uncertainty about identity, purity, and sterility. | Human safety data on injected MOTS-c is essentially nonexistent. MOTS-c is a peptide your own mitochondria already make, but that does not tell us whether dosing extra of it is safe — the safety information that exists comes from short mouse studies, and there is no long-term human data. The most concrete real-world risk is the product itself: it is sold as an unregulated research chemical, so what's actually in a given vial — purity, true dose, sterility — rides on a vendor you're mostly trusting on faith. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
AICAR vs MOTS-c: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.
References
- 1.PubChem — Acadesine (CID 17513)
- 2.Narkar et al., 2008 — AMPK and PPARδ agonists are exercise mimetics (PMID 18674809)
- 3.Newman et al., 2012 — RED-CABG randomized trial (PMID 22782417)
- 4.ClinicalTrials.gov — RED-CABG acadesine study (NCT00872001)
- 5.USADA — What Athletes Should Know About AICAR
- 6.WADA — 2026 Prohibited List